Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Compound CAR T-cells as a" (30 stories)

Top Headline Story

B cell targeted CAR-T therapy for autoimmune diseases
Lead StoryEurekAlert! Science News Releasesworld
Mar 2

B cell targeted CAR-T therapy for autoimmune diseases

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9uTjltc2xDRE9rRjNYVTJkQ2NaSG5PcGFCY0ZfQU9QWGh3OHo2LXRvTjRCbmJmTURFaS1pMWRNRFpVd1dIX2VPZEp0SXRlOWd4UWFMcnpNQ2xrUWdV?oc=5" target="_blank">B cell targeted CAR-T therapy for autoimmune diseases</a>  <font color="#6f6f6f">EurekAlert! Science News Releases</font>

Real-time search volume
1000+20m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

200+20m ago

pope francis

The Myth of St. Francis

500+30m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

1000+30m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Search Results for "Compound CAR T-cells as a"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs
Naturetech

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE83RGpRMUdWNXp4U1IyWGE3S0V4aEhRel9uVEtqSlZlaUNkdFBxLXhIbHljQVhWRUxvV0RDMUNEcFhjY1FWVXJYYlBlU0p5dlJQMUItOW1Oc1puUXNZM05B?oc=5" target="_blank">Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs</a>  <font color="#6f6f6f">Nature</font>

Case Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical case
Frontiersgeneral

Case Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical case

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPQnhIeTZGQXhkSHpDRWJyYjJDV1MyRnEtbTJzbmU0SlF6X3RTRE1LV0szVEp4cU1KUk15cmcxNVJlWUNTMDhNMUpUaWJTYkMyaVNLMV85dlBMMjY5UVJKcjN5UEhIM2lJM21ZMFZrTHgwZGFFT0Q2QmJXdmdmcGw2SF9sRUlEczZpNzVyTU1PaUkyUQ?oc=5" target="_blank">Case Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical case</a>  <font color="#6f6f6f">Frontiers</font>

MIT researchers test electroporation to advance CAR T-cell therapy
Medical Design & Outsourcinggeneral

MIT researchers test electroporation to advance CAR T-cell therapy

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPdEtGUzFLenFULXRtT3dVMjg5Sm1iSEtRMlRfdjVWQ0FTd2kxYUZBVlZkQmJPOVc5UElOSFUwMTkwOVd2RXl5T0FqekdLUzBoU29ROFVIVnhGRFlyMEE2MTc5aTlCMW9saG13SFNvUVhRSXNYV1kzTUxzaEJJNlNEVFVwZDBaQkVvUW4zRVFuLVlXZWNDRnFxLVFDdw?oc=5" target="_blank">MIT researchers test electroporation to advance CAR T-cell therapy</a>  <font color="#6f6f6f">Medical Design & Outsourcing</font>

This Week’s CGT News: CRISPR Hits Phase 3 Milestone
The Medicine Makergeneral

This Week’s CGT News: CRISPR Hits Phase 3 Milestone

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQzNTNjlMMFdUcG5ocHplaThCYjFiNVFaWUZhUHNpNUM5VUthRTJsbUFncktJd3B4aGU5eDExUEYzQURUYXZPbWp6SVlKWkhUbDdxUzYwUWpfUkppOFp6SzVoOTlJaVR1Vkd1THA2eHpqQWltekpMcl9HYlQ5djl2UTZSdFZ6WEdrNTdld0pIa2lJYVdLSmVGSFhjVWwyREYwd3VYMW9WRlg?oc=5" target="_blank">This Week’s CGT News: CRISPR Hits Phase 3 Milestone</a>  <font color="#6f6f6f">The Medicine Maker</font>

Erianin normalizes tumor vessels to boost CAR-T therapy against glioblastoma
Bioengineer.orgtech

Erianin normalizes tumor vessels to boost CAR-T therapy against glioblastoma

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOeWFGbThjcUNScUNlczM5a1U3ckVUSk1iMUFYQzhldHhsekp3M2lGaUthQlpxYmkyeGxheU4tTWxva3NFb1l6ek4wZ3dYY2dhTnI4YmlPMTRaRFFwOFV3SkJ4cDkydXNHdnlVSWp2YjlMaUVQVm5maVZUcEpiaDE5LWVyUXlyNUFZRENTZGx1YU9XTWpLamlKRDBBWlY0V1JUT2VJ?oc=5" target="_blank">Erianin normalizes tumor vessels to boost CAR-T therapy against glioblastoma</a>  <font color="#6f6f6f">Bioengineer.org</font>

Scientists discover how gut bacteria “train” the intestine to fight inflammation
Science Dailytech

Scientists discover how gut bacteria “train” the intestine to fight inflammation

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE12T1ppVllRdEFrdXJ3Z0dhTmlsVXc4bXVpTHU1SXg3LXNKd2tkbUdKazhvZnFmeGRyYm5jREMyeUN4b1UwdFIxN1VEWEc3SDRHcWthNmNIdGhxNGpPZGxoZTZubGVDbWxPanBtUklFMA?oc=5" target="_blank">Scientists discover how gut bacteria “train” the intestine to fight inflammation</a>  <font color="#6f6f6f">Science Daily</font>

CAR-T Cell Therapy Market to Expand at 6.8% CAGR, Driven by Allogeneic and Novel Target Technologies
BigGo Financetech

CAR-T Cell Therapy Market to Expand at 6.8% CAGR, Driven by Allogeneic and Novel Target Technologies

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBCREVvZmFRc20tZ1hxeS1vRkdqaWFzOGNyYVg3Q0lKTGZwSWp5SnBES3R2SHBKRkRMeVoxOEcyQ2Vrc3lHQ0U3OWo2YTJnVEt4RFBYN1Q1VnpwSUZlcHhKNE1yVlBTMzl1SS1YcTU1QjNqRnJBUXc?oc=5" target="_blank">CAR-T Cell Therapy Market to Expand at 6.8% CAGR, Driven by Allogeneic and Novel Target Technologies</a>  <font color="#6f6f6f">BigGo Finance</font>

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis
News-Medicalworld

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQRGg4c0twZTh0SzFQWExJTURPazVFcFdOaWVpa0pGczFZSnctUVZKSVFYT1pqdkdzM0JCMm12T1FBT1NTa2k5R1RWb1Vvcm5MZmM2TVNINm1wUzRBMFVvWXNMbVpqMW13WWg5YzB2VXF3OGFkTFZrUmxxWm1FZUhkMVZOajYwc0NqTjNxNU96azh6blNKYzdieWUwNlNjb01BSW9qRjZ0aHh6bU1CalljSzM1LXFoZGdBUllncWJUT0FKRjUxTmJPTFJB?oc=5" target="_blank">Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis</a>  <font color="#6f6f6f">News-Medical</font>

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR | Stem Cell Reviews and Reports
Springer Nature Linkworld

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR | Stem Cell Reviews and Reports

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBNVTJIeTd6NC1nWmdfZ2dJd0VKNjFUN1J5a1loTjNGYWQ5ejhYRTlGMmJhbkhMeGxnZ1dOd2hPb0tDaHMzYnlNMk5HX3c4N1hsa1FjNVkyRXJCalk0T2lTbWQ5NzVpVmlxekFoSA?oc=5" target="_blank">Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR | Stem Cell Reviews and Reports</a>  <font color="#6f6f6f">Springer Nature Link</font>

BCMA CD19 Targeting CAR Yields Complete Lupus Remission
CGTLive®general

BCMA CD19 Targeting CAR Yields Complete Lupus Remission

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNZEtJSjhtX0Y4T3ljOE9PTzJoS2RDREotc3d4aXVSTTdnRXE0MVhrUlBXazYteFFCNGwyXy1kcTJYVTljb0NYeVprcGFHY0hmM25RaWdYZUU2bXFyVXRtNWFjOWkwR00wN19zQjRUUFFaSFlVTXRBQVpGTGR0YWFCVHhaZw?oc=5" target="_blank">BCMA CD19 Targeting CAR Yields Complete Lupus Remission</a>  <font color="#6f6f6f">CGTLive®</font>

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Natureworld

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9UZFBSUHI3cW9BS19DNldtZVNVU2pVUzlZVi1ob1VYa0VZUVNsdDVKVlVNcXpfYnR6VVV1WTBKa0JueE8zakdOYzAtUTJvSm1HQUZkR1E0aDduVGZqUWc?oc=5" target="_blank">Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia</a>  <font color="#6f6f6f">Nature</font>

Chimeric antigen receptor T-cell therapy in autoimmune diseases
Frontiersworld

Chimeric antigen receptor T-cell therapy in autoimmune diseases

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPUVVKSTEwY2FWb3NQdWhtN1BkdGpKYTJZTVZ4cUxHM1dsOEYweXJKNmlLTk1fWkNDeUhDWEtmUzlKSkZoUjZTSmdoRWwzRUtfeE5wN0doYVlNeXZZcGNNNFE2MUw5N2laeThwcUhJN2dIVmxnODJZajdYalNwR1VGT2RtNTRJTzBGcXN0d0gxeHA4QQ?oc=5" target="_blank">Chimeric antigen receptor T-cell therapy in autoimmune diseases</a>  <font color="#6f6f6f">Frontiers</font>

Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag
Naturegeneral

Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5NblRhZmw2eER2OEhKVzRDM2FuclIyNW5YV20wbENxbHZvWjJoaVI4WjRubGl4YzM2VGFqb0VPSTRnZUF3cTVscV9HNEM1cUdYRXVZNnRmZ25CMy1wVzdn?oc=5" target="_blank">Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag</a>  <font color="#6f6f6f">Nature</font>

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases
Frontiersworld

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOcW9sNE5lLWEwMkRUbWlONW5sZnFMYXRRTk9LV2NZSDVTa3hLSTQ5Slhrc3Z5Z2hORmE5ZHdVbTAzRmNRRk1ieW9CYVdEdGtxM0MwQUhEYXhfYnlOWVJVZkpTQVlldkJSLTBzdmFCYUxxV3Z3UFlldDIzQ01wZTlJYV91ZldncUNqVXFkc3p3?oc=5" target="_blank">CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases</a>  <font color="#6f6f6f">Frontiers</font>

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells
Naturegeneral

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBQNk5qTy1NZU9IX0hfNUJfNUFkaE0xWGFYbWhOOXBXeWJmNm9HNUViaHdSN19xbloyMVBRdFZ3c3puM0ZnRzJRemJBbFR1SXJwRWNqUGlwUHZraTkwMjV3?oc=5" target="_blank">BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells</a>  <font color="#6f6f6f">Nature</font>

Drug-controlled CAR T cells through the regulation of cell–cell interactions
Naturegeneral

Drug-controlled CAR T cells through the regulation of cell–cell interactions

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9BRzRJclk5UmdoaW1WOGtBeC14b2R0SW1vaWpVZXRPc1JGeW0zaG1sU21TRC1Eb3IxTXNYZ2RCeTJPekNfb3ZmdlRsNHdoT2UydS1pRFMzbVRhbXpPZldj?oc=5" target="_blank">Drug-controlled CAR T cells through the regulation of cell–cell interactions</a>  <font color="#6f6f6f">Nature</font>

CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal
Naturegeneral

CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9GdF83ZGJPWmxGQXpvUjBkYVNwb2ZzMlI0d3AwLXBhWm5NaTZrdk14SDBibERkanhOMWJLenFRNDE1T1JvRGFCN0trMTRhdkxjcTFzMWNOR0Fma2RzcnZZ?oc=5" target="_blank">CAR T-cell therapy in multiple myeloma: more room for improvement - Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells
Naturegeneral

A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5zUVJIMTJlbUgwdElRamItU3YxbU1ISHhhQnFUVkNqUE80Tm1PSFV5UlJQZlVYaEY3MnBOb0FfazZxbXJqdG16VEc5eVJ3Yk5FT3JCU05uTHVOODJ3UWhZ?oc=5" target="_blank">A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells</a>  <font color="#6f6f6f">Nature</font>

A cocktail of kinase inhibitors that enhance the antitumor effects of CAR-T cell therapy
Naturetech

A cocktail of kinase inhibitors that enhance the antitumor effects of CAR-T cell therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBobHBWQTd6eW12Wjc2TnFiS1B6aTg1LVQ5RXR4eGxpM3lMS1YwOVVPdHJBbk01UjdXWG5yY3phYWZCQ2dQY3V6WUJSQjhIZzgwdDhkQU1HWXhtM3o5RGdN?oc=5" target="_blank">A cocktail of kinase inhibitors that enhance the antitumor effects of CAR-T cell therapy</a>  <font color="#6f6f6f">Nature</font>

Dual-target CAR T-cell therapy exhibits ‘profound’ remission in systemic sclerosis
Healioworld

Dual-target CAR T-cell therapy exhibits ‘profound’ remission in systemic sclerosis

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQZmtSZ05TRHhQREJYT1ZLTXNHajZDRy1QcWFGalRsZ1k5WUM3VjlMa2psWW53WkMxZFVPS0pCcE1pLTMyV1JRWWtWekNST2JqcmNMTnZtWl9Ub1RaVWU3eW13QlpvV1czV1N1OTgxcEdRc0FSVE1nSVh5cVQzZkpIa2tfaGFLdmtCeW0yWG0wbGZ2Y1lKQ2pUN1JLbE9iXzNhcEszUk5pYlFja1VaYjZ6YjNlRTM0aGhaOUtfT3B4bG1NN2Zka3ZV?oc=5" target="_blank">Dual-target CAR T-cell therapy exhibits ‘profound’ remission in systemic sclerosis</a>  <font color="#6f6f6f">Healio</font>

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
The Lancetworld

CAR T-cell therapy in autoimmune diseases: where are we and where are we going?

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVV9JYjhTYVNFUUh2U1dLVnhmWWtWNXU5a0szRXF2LVFMbEdCQ1BIVU5GalMyS2ttR29ZdXByb0l1Nm1hSnFKeXNSWHRnb1J1c3hKanNJLUprWjI0bUN1MmgzM3BUMmh6U3VmcTh5UWdSV1F1OHdhNm1SdzZHY1JyM2FIV3VTOGpNTEZv?oc=5" target="_blank">CAR T-cell therapy in autoimmune diseases: where are we and where are we going?</a>  <font color="#6f6f6f">The Lancet</font>

Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma | Leukemia
Naturegeneral

Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma | Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE52QzBoOThsTnBHODdQVUdsb3N0Qk04ZjdYYkhObG5IZkNpX0lodnIyS2hsTW1nOUp3eW1KQ1ptM1oxdVlRRnVtaWJxNGVWWW1UdC1FMF8yZjE3TlRSS25N?oc=5" target="_blank">Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma | Leukemia</a>  <font color="#6f6f6f">Nature</font>

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?
Frontiersworld

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQTlRZSzVZMlF5UFRvLWFOYUQ3YUlyNWw4UTdvY1VCVmRVOE1yU3lPQ09seGptNFQ5RjZPZTJBbXpNYkI2bUxiYnl3VkJjNVNnM1h3X1BJT0QtVW8xSG13N0hJVzZNZVBSaV8tbVJQYk5UNEI5amFkcXo3cGxuaEpLYmhCdjFoUk96blpDUVhnT01iUQ?oc=5" target="_blank">CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?</a>  <font color="#6f6f6f">Frontiers</font>

Study links CAR-T cell cancer therapy to ‘brain fog’
Stanford Universitytech

Study links CAR-T cell cancer therapy to ‘brain fog’

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNQ2ZNeGJTNENreTIzckZqMEhRVDJLY1Q0VzZJU1R6cTVxbFBpd3FBN1hLU2szR09iQ2xDZWFvN3E3QTV5elRIREJsMEdUSk1rTEdFa3JkSXFkUnRWX2ZEcUZSTDRuWm9ZT2dPbEFkLTZtaldsOTFzMFA1akR6OXdjWUc1ZjJBVk12dVhwclJHTjE?oc=5" target="_blank">Study links CAR-T cell cancer therapy to ‘brain fog’</a>  <font color="#6f6f6f">Stanford University</font>

A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism | Communications Biology
Natureworld

A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism | Communications Biology

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOWGl0QU05V19wdXBlbXBBUkFqUFd2d0hpbi0weVMtWGUyYzZqSHdXeVZ3Z0U3STZsX2piNXFFT0NMdk9UZV9MYXptUHh5OFp3RWRHX3kyRk9lVFV5N3Bv?oc=5" target="_blank">A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism | Communications Biology</a>  <font color="#6f6f6f">Nature</font>

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Naturetech

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBMZ0F5alBkNmJub0I5TE5fZF9iSl9QMjlWcmxCSktuM2o2Z2JmMVNXMjZhNHBBOHdDWXp1ak1oREkzejV3aDRoMDhHY2FCTkJZS1JQWU1hVVRrZ1h1SnB3?oc=5" target="_blank">Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR</a>  <font color="#6f6f6f">Nature</font>

CD33/CLL1 compound CAR T cells in relapsed/refractory AML
aml-hub.comworld

CD33/CLL1 compound CAR T cells in relapsed/refractory AML

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQenp2VjVTaWJFZjlKRXk0cldZOXZhMVdDLXNhUFptcjVNbzNqSUxjUmo4TXBTR0w5V0tzTkJtYU12QmJiV1UxZGJnR3hWd0RxVkg1aTc1dlVJTjlzeXAzR2h1VW43OHBwZlphQjllQWkxU2R0TVdLSHBNcTh0Q1d5dEJ4Z2FRM2tUTm9McHNHMnNXZTJmMHM5My0tbw?oc=5" target="_blank">CD33/CLL1 compound CAR T cells in relapsed/refractory AML</a>  <font color="#6f6f6f">aml-hub.com</font>

New Data Support CAR T Cells in Difficult Rheumatic Diseases
Medscapegeneral

New Data Support CAR T Cells in Difficult Rheumatic Diseases

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNcXZtZnFQYXY3NzI2ZzRMakYwS0xVbmRmMnZ0aEM1UzJfZk5KeDhtd01pZG9zNGdSZmx4T291dlpBUzczZjhpdzRrU0FKME5HU1lHZ2NGa1ZqNmFuMms4NUc4RkdxMEVYdUdQbHVGYkdJdEtzbndWajNud29uZXYySUNLdXhOY3ZkSHZWQWZRZlphR21zOVlUdExzX3pKbjZnN1J4QV9n?oc=5" target="_blank">New Data Support CAR T Cells in Difficult Rheumatic Diseases</a>  <font color="#6f6f6f">Medscape</font>

CAR-T cell therapy for cancer causes ‘brain fog,’ Stanford Medicine-led study shows
Stanford Medicinetech

CAR-T cell therapy for cancer causes ‘brain fog,’ Stanford Medicine-led study shows

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBiX1JuLWJfZmJYZDVPN0lKeFd1LXRKM0pKLTJDZ2toRUcxV2RtVVV1Z3EwcXM5eGRrQjFpeV9qWU00anVIOHdGeERLZkZodmRUUVlaSTVrUk9zQ2h6aXhzMXVhMjBPRkNfOEwwZmpUMDIxcDYtX1E?oc=5" target="_blank">CAR-T cell therapy for cancer causes ‘brain fog,’ Stanford Medicine-led study shows</a>  <font color="#6f6f6f">Stanford Medicine</font>

"Compound CAR T-cells as a" — Live Google News Trends & Headlines